Literature DB >> 9869219

Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution.

D S Mohan1, J H Suh, J L Phan, P A Kupelian, B H Cohen, G H Barnett.   

Abstract

PURPOSE: To determine the efficacy of definitive surgery and radiation in patients aged 70 years and older with supratentorial glioblastoma multiforme. METHODS AND MATERIALS: We selected elderly patients (> or = 70 years) who had primary treatment for glioblastoma multiforme at our tertiary care institution from 1977 through 1996. The study group (n = 102) included 58 patients treated with definitive radiation, 19 treated with palliative radiation, and 25 who received no radiation. To compare our results with published findings, we grouped our patients according to the applicable prognostic categories developed by the Radiation Therapy Oncology Group (RTOG): RTOG group IV (n = 6), V (n = 70), and VI (n = 26). Patients were retrospectively assigned to prognostic group IV, V, or VI based on age, performance status, extent of surgery, mental status, neurologic function, and radiation dose. Treatment included surgical resection and radiation (n = 49), biopsy alone (n = 25), and biopsy followed by radiation (n = 28). Patients were also stratified according to whether they were optimally treated (gross total or subtotal resection with postoperative definitive radiation) or suboptimally treated (biopsy, biopsy + radiation, surgery alone, or surgery + palliative radiation). Patients were considered to have a favorable prognosis (n = 39) if they were optimally treated and had a Karnofsky Performance Status (KPS) score of at least 70.
RESULTS: The median survival for patients according to RTOG groups IV, V, and VI was 9.2, 6.6, and 3.1 months, respectively (log-rank, p < 0.0004). The median overall survival was 5.3 months. The definitive radiation group (n = 58) had a median survival of 7.3 months compared to 4.5 months in the palliative radiation group (n = 19) and 1.2 months in the biopsy-alone group (p < 0.0001). Optimally treated patients had a median survival of 7.4 months compared to 2.4 months in those suboptimally treated (p < 0.0001). The favorable prognosis group had an 8.4-month median survival compared to 2.4 months in the unfavorable group (p < 0.0001). On multivariate analysis, the KPS, RTOG group, favorable/unfavorable prognosis, and optimal treatment/suboptimal treatment were significant predictors of survival.
CONCLUSION: Elderly patients with good performance status (> or = 70 KPS) when treated aggressively with maximal resection and definitive radiation had longer survival than those treated with palliative radiation and biopsy. Aggressive treatment in such patients should be considered.

Entities:  

Mesh:

Year:  1998        PMID: 9869219     DOI: 10.1016/s0360-3016(98)00296-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  30 in total

1.  Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery.

Authors:  Timothy C Ryken; Bruce Frankel; Terrance Julien; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

2.  Treatment outcomes in glioblastoma patients aged 76 years or older: a multicenter retrospective cohort study.

Authors:  Takeo Uzuka; Kenichiro Asano; Toshio Sasajima; Kaori Sakurada; Toshihiro Kumabe; Takaaki Beppu; Masahiro Ichikawa; Chifumi Kitanaka; Hiroshi Aoki; Kiyoshi Saito; Kuniaki Ogasawara; Teiji Tominaga; Kazuo Mizoi; Hiroki Ohkuma; Yukihiko Fujii; Takamasa Kayama
Journal:  J Neurooncol       Date:  2013-10-31       Impact factor: 4.130

3.  Palliative Radiotherapy of Primary Glioblastoma.

Authors:  Jaspar Witteler; Steven E Schild; Dirk Rades
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

4.  Short-course radiotherapy in elderly patients with glioblastoma: feasibility and efficacy of results from a single centre.

Authors:  L Fariselli; V Pinzi; I Milanesi; A Silvani; M Marchetti; M Farinotti; A Salmaggi
Journal:  Strahlenther Onkol       Date:  2013-04-28       Impact factor: 3.621

5.  Feasibility and response to 1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride chemotherapy with pre-treated procarbazine for elderly patients with newly diagnosed glioblastoma.

Authors:  Mizuhiko Terasaki; Toshi Abe; Naohisa Miyagi; Etsuyo Ogo; Minoru Shigemori
Journal:  J Neurooncol       Date:  2006-08-26       Impact factor: 4.130

6.  Glioblastoma multiforme in the elderly: a therapeutic challenge.

Authors:  A Mangiola; G Maira; P De Bonis; M Porso; B Pettorini; G Sabatino; C Anile
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

7.  Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases.

Authors:  Jacob G Scott; John H Suh; Paul Elson; Gene H Barnett; Michael A Vogelbaum; David M Peereboom; Gene H J Stevens; Heinrich Elinzano; Samuel T Chao
Journal:  Neuro Oncol       Date:  2011-03-01       Impact factor: 12.300

Review 8.  Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis.

Authors:  Saleh A Almenawer; Jetan H Badhiwala; Waleed Alhazzani; Jeffrey Greenspoon; Forough Farrokhyar; Blake Yarascavitch; Almunder Algird; Edward Kachur; Aleksa Cenic; Waseem Sharieff; Paula Klurfan; Thorsteinn Gunnarsson; Olufemi Ajani; Kesava Reddy; Sheila K Singh; Naresh K Murty
Journal:  Neuro Oncol       Date:  2015-01-03       Impact factor: 12.300

9.  Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?

Authors:  Marc Zanello; Alexandre Roux; Renata Ursu; Sophie Peeters; Luc Bauchet; Georges Noel; Jacques Guyotat; Pierre-Jean Le Reste; Thierry Faillot; Fabien Litre; Nicolas Desse; Evelyne Emery; Antoine Petit; Johann Peltier; Jimmy Voirin; François Caire; Jean-Luc Barat; Jean-Rodolphe Vignes; Philippe Menei; Olivier Langlois; Edouard Dezamis; Antoine Carpentier; Phong Dam Hieu; Philippe Metellus; Johan Pallud
Journal:  J Neurooncol       Date:  2017-07-19       Impact factor: 4.130

Review 10.  Radiation therapy for older adults with glioblastoma: radical treatment, palliative treatment, or no treatment at all?

Authors:  Giuseppe Minniti; Riccardo Maurizi Enrici
Journal:  J Neurooncol       Date:  2014-08-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.